Treatment of Advanced Metastatic Melanoma
Keywords:
Metastatic melanoma treatment, anti-PD1, target therapy, metastatic melanoma survival, response rateAbstract
The introduction in clinical practice of new drug compounds both targeted therapies anti-BRAF and checkpoint inhibitors have largely improved our potential to manage advanced metastatic melanoma patients. This has led to a significant improvement in terms of response rates and particularly in the overall survival (OS). The long-term results of trials with follow-up data of patients treated with targeted or immunotherapies reported median OS rates around 24 months, with 5-year survival rates around 35-40%. As to the drugs currently available and reimbursed by the Italian National Health System, 3 combinations of anti-BRAF/anti-MEK inhibitors are available (dabrafenib/trametinib, vemurafenib/cobimetinib and the most recently introduced encorafenib/binimetinib). As for checkpoint inhibitors, first line immunotherapy is represented by anti-PD1 blockers (nivolumab and pembrolizumab), whilst the anti-CTLA-4 ipilimumab can be used as second line immunotherapy. The decision-making factors that define the best treatment approach in stage IV patients with metastatic melanoma include the mutation pattern, performance status, high/low tumor load, brain metastases, progression pattern (low/fast), and availability of clinical trials. This review will analyze the current therapeutic tools adopted for the treatment of metastatic melanoma patients. It will then focus on the latest results obtained by novel treatments (checkpoint inhibitors and targeted therapies) which can be used in the clinical daily practice.
References
Gershenwald JE, Scolyer RA, Hess KR, et al. for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472-492. DOI: 10.3322/caac.21409. PMID: 29028110.
Korn EL, Liu PY, Lee SJ, Chapman JA, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008;26: 527-34. DOI: 10.1200/JCO.2007.12.7837. PMID: 18235113.
Ugurel S, Röhmel J, Ascierto PA, et al. Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. Eur J Cancer. 2020; 130:126-138. DOI: 10.1016/j.ejca.2020.02.021. PMID: 32179447.
Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. Cell 2015; 161:1681-96. DOI: 10.1016/j.cell.2015.05.044. PMID: 26091043.
Keilholz U, Ascierto PA, Dummer R, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31(11):1435-1448. DOI: 10.1016/j.annonc.2020.07.004. PMID: 32763453.
Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015; 386(9992):444-51. DOI: 10.1016/S0140-6736(15)60898-4.
Schadendorf D, Amonkar MM, Stroyakovskiy D, et al. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. Eur J Cancer. 2015;51(7):833-40. DOI: 10.1016/j.ejca.2015.03.004. PMID: 25794603.
Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30-9. DOI: 10.1056/NEJMoa1412690. PMID: 25399551.
Grob JJ, Amonkar MM, Karaszewska B, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015; 16(13):1389-98. DOI: 10.1016/S1470-2045(15)00087-X.
Robert C, Grob JJ, Stroyakovskiy D, et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019; 381(7):626-636. DOI. 10.1056/NEJMoa1904059. PMID: 31166680.
Schadendorf D, Long GV, Stroiakovski D, et al. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. Eur J Cancer. 2017; 82:45-55. DOI: 10.1016/j.ejca.2017.05.033. PMID: 28648698.
Chan MM, Haydu LE, Menzies AM, et al. The Nature and Management of Metastatic Melanoma after Progression on BRAFInhibitors: Effects of Extended BRAF Inhibition. Cancer. 2014,120, 3142–3153. DOI: 10.1002/cncr.28851. PMID: 24985732.
Hassel JC, Buder-Bakhaya K, Bender C, et al. German Dermatooncology Group (DeCOG/ADO). Progression Patterns under BRAF Inhibitor Treatment andTreatment beyond Progression in Patients with Metastatic Melanoma. Cancer Med. 2018,7, 95–104. DOI: 10.1002/cam4.1267. PMID: 29266761.
Atkinson VG, Quaglino P, Aglietta M, et al. Describe III update: a retrospective analysis of dabrafenib and/or dabrafenib + trametinib in patients) with metastatic melanoma. Presented at EADO2019, Paris.
Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014; 371: 1867-76. DOI: 10.1056/NEJMoa1408868. PMID: 25265494.
Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248-60. DOI: 10.1016/S1470-2045(16)30122-X.
Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603-615. DOI: 10.1016/S1470-2045(18)30142-6.
Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018; 19(10):1315-1327. DOI:10.1016/S1470-2045(18)30497-2.
Callahan MK, Flaherty CR, Postow MA. Checkpoint Blockade for the Treatment of Advanced Melanoma. Cancer Treat Res. 2016; 167:231-50. DOI: 10.1007/978-3-319-22539-5_9. PMID: 26601865.
Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363:711–23. DOI: 10.1056/NEJMoa1003466. PMID: 20525992.
Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364:2517–26 DOI: 10.1056/NEJMoa1104621. PMID: 21639810.
Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015; 33:1889–94. DOI: 10.1200/JCO.2014.56.2736. PMID: 25667295.
Ascierto PA, Simeone E, Sileni VC, et al. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access program cohort. J Transl Med. 2014; 12:116. DOI: 10.1186/1479-5876-12-116. PMID: 24885479.
Queirolo P, Boutros A, Tanda E, Spagnolo F, Quaglino P. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. Semin Cancer Biol. 2019; 59:290-297. DOI:10.1016/j.semcancer.2019.08.001. PMID: 31430555.
Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2014; 372:320–30. DOI: 10.1056/NEJMoa1412082. PMID: 25399552.
Robert C, Long GV, Brady B, et al. Five-Year Outcomes with Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma. J Clin Oncol. 2020; 38(33):3937-3946. DOI: 10.1200/JCO.20.00995. PMID: 32997575.
Weber J, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015; 16:375–84. DOI: 10.1016/S1470-2045(15)70076-8.
Larkin J, Minor D, D'Angelo S, et al. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. J Clin Oncol. 2018; 36(4):383-390. DOI: 10.1200/JCO.2016.71.8023. PMID: 28671856.
Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015; 372:2521–32. DOI: 10.1056/NEJMoa1503093. PMID: 25891173.
Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239-1251. DOI: 10.1016/S1470-2045(19)30388-2.
Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015; 16:908–18. DOI: 10.1016/S1470-2045(15)00083-2.
Hamid O, Puzanov I, Dummer R, et al. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer. 2017; 86:37-45. DOI. 10.1016/j.ejca.2017.07.022. PMID: 28961465.
Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016; 17(11):1558-1568. DOI: 10.1016/S1470-2045(16)30366-7.
Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015; 372(21):2006-17. DOI: 10.1056/NEJMoa1414428. PMID: 25891304.
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019; 381(16):1535-1546. DOI: 10.1056/NEJMoa1910836. PMID: 31562797.
McDermott DF, Shah R, Gupte-Singh K, et al. Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis. Qual Life Res. 2019;28(1):109-119. DOI: 10.1007/s11136-018-1984-3. PMID: 30191365.
Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31:3182-3190. DOI: 10.1200/JCO.2012.47.7836. PMID: 23775962.
Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011; 305:2327-2334. DOI: 10.1001/jama.2011.746. PMID: 21642685.
Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011; 29:2904-9. DOI: 10.1200/JCO.2010.33.9275. PMID: 21690468.
Wei X, Mao L, Chi Z, et al. Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study. Oncol Res. 2019;27(4):495-501. DOI: 10.3727/096504018X15331163433914. PMID: 30075827.
Guida M, Bartolomeo N, Quaglino P, et al. On Behalf Of The Italian Melanoma Intergroup Imi Study. No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. Cancers (Basel). 2021; 13(3):475. DOI: 10.3390/cancers13030475. PMID: 33530579.
Dummer R, Schadendorf D, Ascierto PA, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(4):435-445. DOI: 10.1016/S1470-2045(17)30180-8.
Davies MA, Liu P, McIntyre S, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011;117(8):1687-96. DOI: 10.1002/cncr.25634. PMID: 20960525.
Vecchio S, Spagnolo F, Merlo DF, et al. The treatment of melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice, clinical symptoms and outcome with survival. Melanoma Res. 2014;24(1):61-7. DOI: 10.1097/CMR.0000000000000029. PMID: 24121190.
Becco P, Gallo S, Poletto S, et al. Melanoma Brain Metastases in the Era of Target Therapies: An Overview. Cancers (Basel). 2020;12(6):1640. DOI: 10.3390/cancers12061640. PMID: 32575838.
Salvati L, Mandalà M, Massi D. Melanoma brain metastases: review of histopathological features and immune-molecular aspects. Melanoma Manag. 2020;7(2):MMT44. DOI: 10.2217/mmt-2019-0021.
Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18(7):863-873. DOI: 10.1016/S1470-2045(17)30429-1.
Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19(5):672-681. DOI: 10.1016/S1470-2045(18)30139-6.
Tawbi HA, Forsyth PA, Algazi A, et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018;379(8):722-730. DOI: 10.1056/NEJMoa1805453. PMID: 30134131.
Di Giacomo AM, Chiarion Sileni V, Del Vecchio M, et al. Efficacy of ipilimumab plus nivolumab or ipilimumab plusfotemustine vs fotemustine in patients with melanomametastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial. Presented at ESMO 2020. DOI: 10.1016/j.annonc.2020.08.1205.
Trojaniello C, Vitale MG, Ascierto PA. Triplet combination of BRAF, MEK and PD- 1/PD-L1 blockade in melanoma. Curr Opin Oncol 2021; Publish Ah. DOI: 10.1097/CCO.0000000000000709.PMID: 33399314.
Mandalà M, Massi D. Immunotolerance as a Mechanism of Resistance to Targeted Therapies in Melanoma. Handb Exp Pharmacol. 2018; 249:129-143. DOI: 10.1007/164_2017_5. PMID: 28238077.
Ferrucci PF, Di Giacomo AM, Del Vecchio M, et al. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF -mutant melanoma. J Immunother Cancer 2020;8:e001806. DOI: 10.1136/jitc-2020-001806. PMID: 33361337.
Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020 Jun 13;395(10240):1835-1844. DOI: 10.1016/S0140-6736(20)30934-X.
Nathan P, Dummer R, Long GV, et al. LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial. Ann Oncol 2020. DOI:10.1016/j.annonc.2020.08.2273.
AIOM (Associazione Italiana di Oncologia Medica) Melanoma Guidelines. www.AIOM.it
Seth R, Messersmith H, Kaur V, et al. Systemic Therapy for Melanoma: ASCO Guideline. J Clin Oncol. 2020; 38(33):3947-3970. DOI: 10.1200/JCO.20.00198. PMID: 32228358.
Published
Issue
Section
License
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
